- Advertise
- Contact Us
- Contribute
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
- About Us
© 2021 MJH Life Sciences™ and Endocrinology Network. All rights reserved.
Endocrinology
The Endocrinology Network® Endocrinology clinical resource center is a central hub for all endocrine diseases featured on the site. Designed to offer clinicians the latest across multiple fields of endocrinology, this page hosts content related to diabetes, hormone therapy, women’s health, thyroid disorders, and much more. Check back for news on FDA approvals, the latest studies, conference coverage, case reports, and guideline updates.
Gender-Affirming Hormone Therapy Linked to Blood Pressure Changes in Transgender Individuals
April 20, 2021
The largest study of its kind is providing insight related to changes in blood pressure seen among transgender patients initiating gender-affirming hormone therapy.
FDA Makes Historic First Approving NEXTSTELLIS, an Oral Contraceptive Containing E4
April 20, 2021
The approval, which was awarded to Mayne Pharma, makes NEXTSTELLIS the first and only contraceptive pill containing E4, a natural occurring estrogen to receive approval from the FDA.
Exposure to Endocrine-Disrupting Chemicals Can Increase Risk of Postpartum Depression
April 02, 2021
An analysis of nearly 150 pregnant women presenting NY-based medical centers suggests prenatal exposure to endocrine-disrupting chemicals in plastics could increase odds of developing postpartum depression.
Daily Semaglutide Effective for Nonalcoholic Steatohepatitis in Phase 2 Trial
March 30, 2021
A phase 2 trial examining the effects of daily semaglutide over a 72-week period suggests the GLP1-RA could help patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) achieve NASH resolution.
Teprotumumab Linked to Hearing Loss, Tinnitus in New Study
March 26, 2021
A single-center study presented at ENDO 2021 suggests more than half of the patients with thyroid eye disease patients treated with teprotumumab (Tepezza) developed otologic symptoms.
Dasiglucagon (Zegalogue) Approved by FDA for Severe Hypoglycemia in Children and Adults
March 22, 2021
Zealand Pharma announced the US FDA approved dasiglucagon (Zegalogue) for treatment of severe hypoglycemia in patients with diabetes aged 6 and older and the injectable will be available as both an auto injector and a prefilled syringe.
SGLT2 Inhibitor Use is Safe, Efficacious in Kidney Transplant Patients with Diabetes, Study Finds
March 22, 2021
A literature review of studies assessing SGLT2 inhibitor use in kidney transplant patients with diabetes suggests use did not impact graft function and was associated with improvements in glucose control and body weight.
Black Women with PCOS at Greater Cardiometabolic Risk than White Counterparts
March 22, 2021
A meta-analysis of nearly a dozen studies presented at ENDO 2021 suggests Black women with PCOS were at an increased cardiometabolic risk, despite having comparable fasting glucose and lower triglyceride levels.
Thyroid Combination Therapy Preferred Over Levothyroxine for Some Hypothyroidism Patients
March 21, 2021
A randomized, 3-arm study is giving further insight into the effects of levothyroxine monotherapy compared against a thyroid combination therapy and desiccated thyroid extract for management of hypothyroidism, particularly in patients with Thr92AlaD2 polymorphism.
Many Endocrine Providers, Patients Open to Continuing Telehealth Practices
March 21, 2021
An analysis of patients and providers from endocrine clinics suggests many patients and providers were open to continuing with telehealth practices after the pandemic and many saw little to no limitations with the new practices.